The biotech industry continues to play a crucial role in developing solutions to treat critical ailments. In addition, the demand for biotech solutions is also high across other...
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more...
Leap Therapeutics, Inc. (NASDAQ:LPTX) announced that it has entered into an exclusive option and license agreement with China-based biopharmaceutical company, BeiGene, Ltd....
For Immediate ReleaseChicago, IL – September 27, 2019 - Stocks in this week’s article are Columbia Sportswear Company (NASDAQ:COLM) , American Woodmark Corp....
A common investing technique is to hunt for stocks with a low price-to-earnings (P/E) ratio. That’s because this basic measure of how much investors are spending for $1 worth...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Strong Sell | Neutral | Buy |
| Technical Indicators | Sell | Strong Sell | Strong Sell | Strong Sell | Strong Buy |
| Summary | Sell | Strong Sell | Strong Sell | Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 131.72 | 132.06 | 129.86 | +0.13 | +0.10% | 825.69K | NASDAQ | |||
| 144.47 | 144.70 | 143.16 | -0.37 | -0.26% | 23.84M | NASDAQ | |||
| 331.23 | 331.84 | 327.50 | +6.47 | +1.99% | 6.25M | NASDAQ | |||
| 2,839.40 | 2,844.40 | 2,823.00 | +12.1 | +0.43% | 246.50K | NASDAQ | |||
| 325.77 | 328.11 | 325.65 | -3.33 | -1.01% | 178.59K | NASDAQ | |||
| 626.27 | 632.50 | 621.00 | -2.02 | -0.32% | 1.33M | NASDAQ | |||
| 8.60 | 8.74 | 7.67 | +1.210 | +16.37% | 64.73M | NASDAQ | |||
| 292.08 | 296.98 | 271.60 | +11.47 | +4.09% | 5.03M | NASDAQ | |||
| 167.92 | 168.97 | 166.60 | -0.08 | -0.05% | 3.87M | NYSE | |||
| 41.60 | 41.66 | 41.05 | +0.11 | +0.27% | 6.80M | NYSE | |||
| 219.89 | 221.17 | 216.50 | +1.27 | +0.58% | 5.95M | NASDAQ | |||
| 94.93 | 97.93 | 92.88 | +2.20 | +2.37% | 1.74M | NYSE | |||
| 38.45 | 38.59 | 37.27 | +0.74 | +1.98% | 13.24M | NYSE | |||
| 69.76 | 69.93 | 69.22 | +0.10 | +0.14% | 507.27K | NYSE | |||
| 121.60 | 123.21 | 119.54 | -6.15 | -4.81% | 3.91M | NYSE |
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company has two product pipelines: DKN-01 and TRX518. The Company's lead clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a cell secreted protein that research has found its role in embryonic development. DKN-01 is an affinity, neutralizing monoclonal antibody targeting DKK1. DKN-01 reduces free DKK1 levels and has demonstrated an anti-tumor effect in preclinical models. TRX518 is a humanized anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody designed for the immune system’s anti-tumor response as an immune checkpoint agonist.